Drug Profile
Echinomycin - OncoImmune
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator OncoImmune
- Class Cytostatic antibiotics
- Mechanism of Action DNA synthesis inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 29 Mar 2016 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to March 2016 (OncoImmune pipeline, March 2016)